North America Liver Disease Treatment Market Forecast to Reach US$ 12.28 Billion by 2031 Amid Advancements in Targeted Therapies | DataM Intelligence

According to DataM Intelligence, the North America Liver Disease Treatment Market reached US$ 7.9 billion in 2023 and is expected to reach US$ 12.28 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031. Market growth is driven by increasing prevalence of liver disorders such as hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cancer, growing investments in R&D for novel therapies, and rising demand for advanced treatment options across clinical care settings.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/north-america-liver-disease-treatment-market?jd

North America Key Industry Developments
✅ November 2025: Gilead Sciences announced long-term real-world data reinforcing the safety and sustained efficacy of Livdelzi® (seladelpar) in patients with primary biliary cholangitis (PBC), demonstrating significant reductions in key biomarkers and chronic itch, offering a promising alternative for patients switching from obeticholic acid or as second-line therapy.
✅ Late 2025: The U.S. non-alcoholic steatohepatitis (NASH) treatment segment saw regulatory progress with accelerated approvals and expanded indication opportunities for metabolic disease-focused therapies such as semaglutide (Wegovy) in MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis, supporting broader treatment adoption.

Key Mergers and Acquisitions:
✅ October 2025: A leading biopharma company acquired a clinical-stage NASH therapeutic developer to strengthen its liver disease treatment pipeline and accelerate commercialization of innovative therapies.
✅ September 2025: A major North American pharmaceutical firm completed the acquisition of a specialty biotech focused on targeted liver cancer therapies, expanding its oncology portfolio and advanced liver disorder treatment capabilities.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=north-america-liver-disease-treatment-market
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis
-By Treatment Type: Antiviral Drugs and Targeted Therapy Leading Adoption
Antiviral drugs hold a significant share due to high demand for hepatitis treatment, while targeted therapies are rapidly gaining traction for liver cancer and advanced liver disease management. Immunosuppressants, corticosteroids, vaccines, and immunoglobulins also contribute to comprehensive therapeutic strategies.

-By Disease Type: Hepatitis Dominates, NAFLD and Liver Cancer on the Rise
Hepatitis remains the largest disease segment due to widespread incidence and long-term treatment requirements. Non-alcoholic fatty liver disease (NAFLD) and liver cancer represent high-growth segments supported by increased clinical research focus and therapeutic innovation.

-By End User: Hospitals and Specialty Clinics Lead Market Demand
Hospitals and specialty clinics account for the largest share of treatment demand due to availability of comprehensive care, advanced diagnostics, and multidisciplinary treatment protocols. Ambulatory surgery centers and others are also gaining share as outpatient treatment trends increase.

Regional Insights
The North America Liver Disease Treatment Market is primarily driven by strong healthcare infrastructure, high disease awareness, and robust pharmaceutical innovation ecosystems in the United States and Canada. Widespread adoption of advanced treatment technologies, supportive reimbursement frameworks, and increasing clinical research activities contribute to sustained market growth.

Growth Drivers:
1. Rising Prevalence of Liver Disorders: Increasing incidence of hepatitis, NAFLD, and liver cancer drives therapeutic demand.
2. Advanced Therapeutic Innovation: Development of targeted therapies, immunomodulators, and combination regimens expands treatment options.
3. Growth in Clinical Research Activities: Ongoing clinical trials and government support accelerate new therapy approvals.
4. Improved Healthcare Infrastructure: Advanced diagnostic and treatment facilities support early detection and effective care.
5. Expansion of Outpatient Care Services: Rise in ambulatory treatment settings enhances patient access and convenience.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/north-america-liver-disease-treatment-market?jd

Key Players:
The major players in the North America Liver Disease Treatment Market include Pfizer Inc., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., and Gilead Sciences Inc., among others.

Key Highlights (Top 5 Key Players):
1. Gilead Sciences Inc. is a leader in antiviral therapies for hepatitis and advanced liver disease treatments.
2. Pfizer Inc. drives market growth with innovative targeted and immunomodulatory therapies.
3. AbbVie Inc. focuses on advanced combination therapy regimens for chronic liver disorders.
4. F. Hoffmann-La Roche Ltd leverages strong oncology expertise for liver cancer treatment portfolios.
5. Novo Nordisk A/S is expanding its presence in metabolic liver disease treatment through clinical research and pipeline development.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply-Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.